Immune Repertoire Sequencing Market – Insights
Immune repertoire sequencing is extensively used in biomarker discovery to improve the success rate and cost-effectiveness of rational drug development. For instance, in November, 2017, the Center for Commercialization of Cancer Immunotherapy (C3i) started offering T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit in Canada. Increasing demand for personalized medicine, in turn, is expected to aid the immune repertoire sequencing market growth, as personalized medicine uses an individual’s genetic profile to guide decisions made in regard to the diagnosis, prevention, and treatment of diseases.
The global immune repertoire sequencing market size was valued at US$ 114.3 million in 2017, and is expected to witness a CAGR of 5.6% over the forecast period (2018 – 2026).
Global Immune Repertoire Sequencing Market Share (%) Analysis, By Product Type, 2017
Source: Coherent Market Insights Analysis (2018)
Increasing Research & Development and Demand for Genomic and Repertoire Sequencing-based Research is expected to Drive Growth of the Immune Repertoire Sequencing Market
Increasing research and development and launches of novel products by key players are expected to be the major driving force for global immune repertoire sequencing market growth in the near future. For instance, in 2016, ArcherDX, Inc. expanded its product portfolio with the launch of Archer Immunoverse immune repertoire sequencing assays at the American Society of Hematology (ASH). In 2017, ArcherDX, Inc. launched Archer Immunoverse B Cell Receptor (BCR) assays to characterize the human B cell repertoire.
According to a study published by Cold Spring Harbor Laboratory, in 2017, researchers from Stanford University applied immune repertoire sequencing to identify disease-related signatures in the immune systems of patients with systemic sclerosis-related pulmonary hypertension (SSc-PAH), a rare chronic autoimmune disease that affects the connective tissue. Therefore, increasing research on immune repertoire sequencing is expected to create a favorable environment for immune repertoire sequencing market growth in the near future.
Immune Repertoire Sequencing Market - Restraints
Challenges in immune repertoire sequencing include distinguishing biological variations from the errors and the bias introduced in different steps. Conventional and novel bioinformatics techniques such as high throughput screening, Haystack Heuristic, and others are not up to the mark due to unsatisfactory scalability and sensitivity, and limitation in providing sufficient and accurate data. Moreover, the differences of data generation and processing in different laboratories along with the challenges in immune repertoire sequencing system are some key factors, which may hamper growth of the immune repertoire sequencing market size.
Immune Repertoire Sequencing Market - Regional Insights
On the basis of region, the global immune repertoire sequencing market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global immune repertoire sequencing market during the forecast period, owing to high presence of key industry players in the region (including Illumina Inc., Thermo Fisher Scientific, Pacific Biosciences, and CD Genomics). These players are increasingly focusing on development of novel technologies for immune repertoire sequencing. For instance, in 2017, 10x Genomics Inc., U.S. based company, added B-Cell and 5’Unbiased Enrichment Kit to its chromium immune repertoire profiling solution or immune repertoire sequencing.
Europe is expected to foresee a rapid growth in the immune repertoire sequencing market. The market in Europe is expected to gain momentum during the forecast period, owing to rise in funding by the government bodies to support international innovative projects and marketable innovative products, processes, and services, in order to cater unmet medical need. In July 2018, Eurostars (a joint program between EUREKA and the European Commission) granted US$ 495,000 to OSE Immunotherapeutic SA’s project entitled: ‘Treatment Response Monitoring for Cancer Immunotherapies Using Immune Repertoire Analysis’.
Global Immune Repertoire Sequencing Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2026
Source: Coherent Market Insights Analysis (2018)
Immune Repertoire Sequencing Market - Competitive Landscape
Key players operating in the global immune repertoire sequencing market include Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies, Oxford Nanopore Technologies, Ltd., Qiagen N.V., Agilent Technologies, Inc., and Takara Bio, Inc.